Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ABOS

Acumen Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1576885Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(121.0M)
EPS (Basic, as reported)
$-2.00
Net Margin FY2025
—
ROE FY2025
-172.3%
Total Equity
$70.0M
Shares Out
72M
Business description

Acumen Pharmaceuticals, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (7) → (121)
Fiscal yearFY2020FY2021⚑FY2022FY2023FY2024FY2025
Research & development(8)(12)(32)(42)(94)(105)
General & administrative(1)(7)(13)(19)(20)(19)
Total operating expenses(9)(20)(45)(61)(114)(124)
Operating income(8)(20)(45)(61)(114)(124)
Interest expense——0(1)(4)(4)
Interest & investment income——211147
Other income (expense), net1(81)29122
Income tax expense000000
Net income(7)(101)(43)(52)(102)(121)
EPS — basic—($5.02)($1.06)($1.08)($1.71)($2.00)
EPS — diluted—($5.02)($1.06)($1.08)($1.71)($2.00)
Shares outstanding — basic (M)—2041496061
Shares outstanding — diluted (M)—2041496061
  • ⚑ Weighted-average shares changed ×2.05 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.